Visualization of mitotic arrest of cell cycle with bioluminescence imaging in living animals

Molecular Imaging and Biology

Volumn 15, Issue 4, 2013, Pages 431-440

  Zhang, Guo Jun ^a,b   Chen, Tsing Bau ^b   Davide, Joseph ^b   Tao, Weikang ^b   Vanko, Amy ^b   Connolly, Brett ^b   Williams Jr , David L ^b   Sur, Cyrille ^b  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bioluminescence; Cell cycle; Cyclin B1; Mitotic arrest; Optical imaging

Indexed keywords

CYCLIN B1; DOCETAXEL; LUCIFERASE; PACLITAXEL; PROTEASOME; PROTEIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRAIN HCT116; CONTROLLED STUDY; GENETIC TRANSFECTION; HELA CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UBIQUITINATION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CYCLIN B1; HCT116 CELLS; HELA CELLS; HISTONES; HUMANS; LUCIFERASES; LUMINESCENCE; MICE; MITOSIS; MOLECULAR IMAGING; NOCODAZOLE; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN STABILITY; PROTEOLYSIS; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; SUBCUTANEOUS TISSUE; TAXOIDS; UBIQUITINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 84880333400     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-013-0619-x     Document Type: Article

References (24)

1. Loog M, Morgan DO (2005) Cyclin specificity in the phosphorylation of cyclin-dependent kinase substrates. Nature 434:104-108
2. Lukas J, Bartek J (2004) Cell division: the heart of the cycle. Nature 432:564-567
3. Jackson JR, Patrick DR, Dar MM, Huang PS (2007) Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7:107-117
4. Schmidt M, Bastians H (2007) Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 10:162-181
5. Gascoigne KE, Taylor SS (2009) How do anti-mitotic drugs kill cancer cells? J Cell Sci 122:2579-2585
6. Rudin M, Weissleder R (2003) Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2:123-131
7. Monga M, Sausville EA (2002) Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia 16:520-526
8. Bednar B, Zhang GJ, Williams DL, Hargreaves R, Sur C (2007) Optical molecular imaging in drug discovery and clinical development. Expert Opin Drug Discov 2:65-85
9. Glotzer M (1995) Cell cycle. The only way out of mitosis. Curr Biol 5:970-972
10. Murray A (1995) Cyclin ubiquitination: the destructive end of mitosis. Cell 81:149-152
11. Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner MW et al (2004) Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 428:194-198
12. Garbaccio RM, Tasber ES, Neilson LA, Coleman PJ, Fraley ME et al (2007) Kinesin spindle protein (KSP) inhibitors. Part 7: design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 17:5671-5676
13. Zhang GJ, Chen TB, Bednar B, Connolly BM, Hargreaves R et al (2007) Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of anticancer drugs and target validation. Neoplasia 9:652-661
14. Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P et al (2004) Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med 10:643-648
15. Tao W, South VJ, Zhang Y, Davide JP, Farrell L et al (2005) Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 8:49-59
16. Hadjantonakis AK, Papaioannou VE (2004) Dynamic in vivo imaging and cell tracking using a histone fluorescent protein fusion in mice. BMC Biotechnol 4:33
17. Wang W, El-Deiry WS (2003) Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther 2:196-202
18. Luker GD, Pica CM, Song J, Luker KE, Piwnica-Worms D (2003) Imaging 26S proteasome activity and inhibition in living mice. Nat Med 9:969-973
19. King RW, Peters JM, Tugendreich S, Rolfe M, Hieter P et al (1995) A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. Cell 81:279-288
20. Yamano H, Tsurumi C, Gannon J, Hunt T (1998) The role of the destruction box and its neighbouring lysine residues in cyclin B for anaphase ubiquitin-dependent proteolysis in fission yeast: defining the D-box receptor. EMBO J 17:5670-5678
21. Hagting A, Jackman M, Simpson K, Pines J (1999) Translocation of cyclin B1 to the nucleus at prophase requires a phosphorylation-dependent nuclear import signal. Curr Biol 9:680-689
22. Lukas C, Sorensen CS, Kramer E, Santoni-Rugiu E, Lindeneg C et al (1999) Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 401:815-818
23. Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G et al (2007) The role of Aurora-A inhibitors in cancer therapy. Ann Oncol 18(Suppl 6):vi47-vi52
24. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H et al (2008) Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 132:487-498